SV-BR Cancer Cell Lines for Targeted Immunotherapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for diagnosing and treating cancers such as breast, ovarian, and lung cancer are ineffective, leading to high mortality rates due to difficulties in detection and treatment.

Innovation Solution

Development of novel cell lines, specifically the SV-BR cancer cell lines, which exhibit unique characteristics such as sensitivity to certain drugs and karyotypic abnormalities, are used to induce an immune response and treat cancer through therapeutic compositions and vaccines.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional cancer therapies are used, then cancer treatment is attempted, but effectiveness is poor and mortality rates remain high

Engineering Contradiction:

Improvecancer treatment effectivenessVSAvoidmortality rate

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the parameters of cancer cell lines by selecting and cultivating cells with specific characteristics (her2/neu overexpression, sensitivity to specific drugs, karyotypic abnormalities) to create SV-BR cell lines that can serve as effective cancer vaccines, transforming conventional treatment approaches into a targeted immunotherapy approach

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses SV-BR cancer cell lines as a copy or model of actual cancer cells to develop vaccines that train the immune system to recognize and attack real cancer cells, allowing indirect treatment without direct exposure to harmful cancer materials

Inventive Principle:

Principle #26Copying

2Measurement precision

If cancer detection methods are used, then diagnosis is attempted, but detection difficulty remains high

Engineering Contradiction:

Improvecancer detection accuracyVSAvoiddetection difficulty

Core Design Contradiction:

Measurement precisionVSDifficulty of detecting and measuring

Solution Approach 1:

The SV-BR cell lines serve as an intermediary tool that expresses specific tumor markers and antigens, making cancer detection more accessible through standardized cell-based assays rather than requiring complex direct tumor detection methods

Inventive Principle:

Principle #24Intermediary (Mediator)

3Adaptability or versatility

If existing cancer treatments are applied, then therapy is provided, but adaptability to different cancer types is limited

Engineering Contradiction:

Improvetreatment adaptabilityVSAvoidtreatment effectiveness

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The SV-BR cell line platform can be adapted to treat multiple cancer types (breast, ovarian, lung) by selecting cell lines with appropriate characteristics for each cancer type, providing a universal vaccine platform that maintains high effectiveness across different cancers

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS7674456B2Breast cancer cell lines and uses thereof

Publication Date: 2010.03.09 BRIACELL THERAPEUTICS CORP

AI summary

The invention provides, in part, novel SV-BR cancer cell lines. The invention provides a novel cell line SV-BR-1 deposited under ATCC PTA-1712 and SV-BR-1-GM cells deposited under ATCC PTA-1713. The invention further relates to therapeutic and non-therapeutic uses of the novel cell lines. Therapeutic uses include the use of SV-BR cell lines as cancer vaccines, and in particular, or the treatment of cancer.